CAR-T Technology for Recurrent/Refractory Malignant Hematological and Lymphatic Tumors
Trial statusNot yet recruiting
Trial phasePhase 1
Trial typeInterventional
Biological sexAll
Age14-75
SponsorMingzhi Zhang
About this trial
evaluate the safety and Esfficacy of CAR-T technology for the treatment of recurrent/refractory malignant hematological lymphomas
Eligibility criteria
Qualifiers
The participant has given informed consent and signed the consent form, and is willing and capable of complying with the scheduled visits, study treatment, laboratory examinations, and other trial procedures.
Anti-CD20 monoclonal antibodies
Combination chemotherapy containing anthracyclines.
Age 14-75 years (inclusive), both male and female.
Disqualifiers
History of any of the following cardiovascular diseases within the past 6 months: New York Heart Association (NYHA) class III or IV heart failure, cardiovascular intervention (angioplasty or stenting), myocardial infarction, unstable angina, or other clinically significant heart diseases.
History of severe pulmonary dysfunction.
Concurrent advanced malignant tumors.
Concurrent systemic fungal, bacterial, viral, or other infections that cannot be effectively controlled.
Trial design
Treatments tested in this trial
- CAR-T Therapy
Treatment groups
30 Participants
are divided into 1 treatment groupSponsors and collaborators
Mingzhi Zhang
Lead sponsor
Zhengzhou University
Sponsor institution
Source ClinicalTrials.gov